In partnership with



Lowest error rate on real dictation. Ahead of Google, OpenAI

Speech models love clean lab audio. Your real prompts don't sound like that. So Wispr Flow tested its in-house speech model, Canto, on 10 hours of real dictations from 2,300+ speakers.

The result: the lowest word error rate of every model tested, including models from Google, OpenAI, AssemblyAI and Deepgram. It also tied for the lowest error rate on LibriSpeech, a standard public benchmark.

For you, that means fewer fixes and longer, richer prompts. Speak your context, constraints and examples into ChatGPT or Claude, and Wispr Flow turns it into clean text in any app. Works on Mac, Windows, iPhone and Android.



What if you already knew what to do? 

SEC Form 4 insider transaction filing on a desk with Liquidia, Chili's, and Procter & Gamble logos nearby.

Key Points

  • Liquidia insiders have sold shares amid a patent settlement and analyst price-target cuts, though institutional buying and rising YUTREPIA sales offer some offsetting support.
  • Brinker International insiders sold heavily during a successful Chili's turnaround, but strong sales growth, margin gains, and analyst optimism suggest the sales are less concerning.
  • Procter & Gamble's insider sales appear tied to routine prearranged trading plans, with analysts bullish on the stock and the company maintaining strong cash flow and dividend growth.
  • Special Report: Today's stock pick is on me 

 

Insider trading sends many signals, but not all of them are what they seem.

Insider selling can be a green light for investors or a warning to stay away; it depends on the market. Sector trends, the business cycle, and a company's profit outlook all influence how investors should interpret those transactions. All else being equal, profitable companies are more valuable than those that aren’t, separating true investments from speculation and risk.


Five tickers can still share one risk (Ad)

The vote ended. Your portfolio risks remain. Several tickers can share the same exposure. Explore our five-stock portfolio-resilience report, then compare the ideas with what you already own. Start the review before reacting to the next headline.

Let me see the report



Liquidia Insiders Liquidate After Bad News

Liquidia (NASDAQ: LQDA) is a commercial-phase biopharma company that reported bad news this year. Its primary treatment, YUTREPIA, faced a setback after a September patent ruling, but an October settlement with United Therapeutics resolved the litigation. Liquidia can continue selling YUTREPIA for pulmonary arterial hypertension, although it must stop promoting the drug for a separate indication and make substantial settlement payments. The agreement creates financial challenges, but the company's growing sales provide some relief. In Q3, YUTREPIA sales climbed 31% sequentially to $222.7 million, even as Liquidia recorded a $389.7 million charge related to the settlement.

To make matters worse, insiders are selling into the correction, helping depress shares.

Insiders own 25% of LQDA shares and are a significant force, with at least nine executives with Chief in their title selling since the patent court ruling. Prearranged trading plans account for some of these sales, allowing executives to capitalize on high share prices and manage share-based compensation. However, not all transactions fall under these plans. Many of these trades are open-market sales, suggesting a top-heavy managerial team may be trimming excess risk.

Wall Street's outlook for Liquidia has weakened, adding to the stock's challenges.

Many analysts have slashed their price targets in recent months, reflecting growing concerns about Liquidia's outlook. Shares traded well below the $72.85 consensus target in early November, although that gap also suggests potential upside if the company's operating performance continues to improve.

Institutions own about 65% of Liquidia shares, but institutional buying has exceeded selling over the past 12 months. Despite the recent insider selling, institutional support and improving sales could help offset some of the stock's downward pressure.

Liquidia stock chart illustrating where LQDA sold off on bad news.

Chili’s Insiders Reap Rewards of Successful Turnaround

Chili’s parent company Brinker International (NASDAQ: EAT) saw heavy insider selling in Q3 and early Q4, but the company's strong operating performance suggests those sales may be less concerning than they initially appear.

The sales came after two years of improving results, strong comparable sales, and margin gains tied to a strategy shift. Chili's has embraced a “better-than-fast-food” approach, offering value meals and beverages that resonate with consumers. The strategy has helped drive sustained sales growth, widening margins, and accelerating earnings, with Chili’s sales up more than 50% in the three-year stack.

Analysts like what they are seeing from EAT. Coverage has increased, sentiment has strengthened, and price targets have climbed, supporting the stock's Moderate Buy consensus rating. The average price target is up more than 50% over the past 12 months, and implies more than 20% from October’s lows. Reaching that target would put shares at a fresh all-time high.

The fiscal Q2 results due in early 2027 could provide another catalyst for analysts to raise their targets if the company's momentum continues.

Institutions own approximately 99% of EAT shares and have been net buyers this year, signaling confidence in the company's turnaround. The risk is that they distributed shares in early Q4 and may continue to do so, limiting upside until the FQ2 release. Improving performance at non-core brands, expanding margins, strong cash flow, and sustained comparable sales growth could encourage institutions to increase their holdings.

Brinker stock chart showing EAT in the midst of a growth spurt.


After the midterms: question your stock shortlist (Ad)

The vote is over. Is your watchlist too familiar? Explore seven hidden-gem stock ideas beyond your usual tickers. Read our free report, then examine each business and its risks before deciding what deserves a closer look.

Let me see the report



Procter & Gamble Insider Sales Raise Few Red Flags

Insider selling of Procter & Gamble (NYSE: PG) shares is not a red flag. The spotty, sometimes large, share sales are linked to prearranged trading plans, intended to maintain diversification and manage options exercises tied to share-based compensation.

Executives still own a significant stake, while the company's established business and strong cash flow help offset ongoing cost pressures.

The main hurdle for Procter & Gamble is consumers shifting to cheaper alternatives, which could pressure sales and profitability. However, the company's broad product portfolio gives it an advantage, allowing it to serve budget-conscious consumers without relying solely on premium-priced products.

Analysts are bullish on PG stock. Of the 26 analysts covering Procter & Gamble, 15 rate it a Buy and 11 a Hold, giving the stock a Moderate Buy consensus rating. Price targets have also climbed, with the average around $170. Continued upward revisions could signal greater confidence in the company's outlook and support further share-price gains.

Investors should consider Procter & Gamble’s cash flow and profitability, which support healthy capital returns. Capital returns include share buybacks and dividends, including distribution growth.

The company is a Dividend King, yielding around 2.6%, and able to sustain annual distribution increases for the foreseeable future.

Procter & Gamble's acquisition of Thorne HealthTech could drive growth by expanding its presence in premium, practitioner-focused, subscription-based healthcare. However, rising input costs have already pressured margins, and further increases could weigh on profitability.

Procter & Gamble stock chart showing PG in rally mode.

Read this article online ›pixel

 

Add MarketBeat as a Google Preferred Source

 

Stay Ahead of the Market

The best investment opportunities don't wait. Get our research and stock ideas delivered straight to your smartphone—so you never miss a market-moving opportunity. Our text alerts ensure you see timely stock ideas and professional research reports instantly, whether you're in a meeting, commuting, or away from your desk.

Get Text Alerts from American Market News (free)